HomeCompareMLLCF vs EPRT

MLLCF vs EPRT: Dividend Comparison 2026

MLLCF yields 40.32% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MLLCF wins by $172.6K in total portfolio value
10 years
MLLCF
MLLCF
● Live price
40.32%
Share price
$4.96
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$236.0K
Annual income
$40,141.97
Full MLLCF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — MLLCF vs EPRT

📍 MLLCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMLLCFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MLLCF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MLLCF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MLLCF
Annual income on $10K today (after 15% tax)
$3,427.42/yr
After 10yr DRIP, annual income (after tax)
$34,120.67/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, MLLCF beats the other by $23,206.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MLLCF + EPRT for your $10,000?

MLLCF: 50%EPRT: 50%
100% EPRT50/50100% MLLCF
Portfolio after 10yr
$149.7K
Annual income
$26,491.34/yr
Blended yield
17.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

MLLCF
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
-1.2
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MLLCF buys
0
EPRT buys
0
No recent congressional trades found for MLLCF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMLLCFEPRT
Forward yield40.32%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$236.0K$63.4K
Annual income after 10y$40,141.97$12,840.73
Total dividends collected$178.0K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: MLLCF vs EPRT ($10,000, DRIP)

YearMLLCF PortfolioMLLCF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$14,732$4,032.26$11,205$505.18+$3.5KMLLCF
2$21,315$5,551.80$12,672$682.46+$8.6KMLLCF
3$30,314$7,507.11$14,490$930.48+$15.8KMLLCF
4$42,415$9,978.09$16,786$1,282.69+$25.6KMLLCF
5$58,431$13,047.54$19,753$1,791.56+$38.7KMLLCF
6$79,320$16,798.63$23,677$2,541.64+$55.6KMLLCF
7$106,185$21,312.20$29,008$3,672.99+$77.2KMLLCF
8$140,281$26,663.87$36,463$5,425.08+$103.8KMLLCF
9$183,022$32,921.38$47,238$8,221.57+$135.8KMLLCF
10$235,976$40,141.97$63,385$12,840.73+$172.6KMLLCF

MLLCF vs EPRT: Complete Analysis 2026

MLLCFStock

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Full MLLCF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this MLLCF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MLLCF vs SCHDMLLCF vs JEPIMLLCF vs OMLLCF vs KOMLLCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.